AMPLIFY-7P randomised ph2
✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile
➡️curative intent & no recurrence <6mth #PDAC
✅T cell responses,primary endpt-ve
➡️benefit in ctDNA-ve& no rads?
➡️DFS @6mth benefit of 14% p=0.056
✅ph3 planned
@myESMO @OncoAlert #ESMO26
452 浏览 · 9 赞 · 13 转发 · 1 回复
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.orgSeven-valent mKRAS-specific lymph node targeted amphiphile immunotherapy versus observation in resected pancreatic ductal adenocarcinoma (PDAC): The AMPLIFY-7P randomized phase 2 study
https://esmocongress.esmo.org- Santhosh Ambika@RenoHemonc
@graokane @myESMO @OncoAlert Neoantigen based probably better than off the shelf ?
来源：Grainne O'Kane · x.com